HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KR-36996

a urotensin II receptor antagonist; structure in first source

Also Known As:

N-(1-(3-bromo-4-(piperidin-4-yloxy)benzyl)piperidin-4-yl)benzo(b)thiophene-3-carboxamide

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - KR-36996: 2
  - Piperidines: 17
    - KR-36996: 2
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - KR-36996: 2

Experts

1.	Lee, Byung Ho: 2 articles (05/2017 - 03/2017)
2.	Yi, Kyu Yang: 2 articles (05/2017 - 03/2017)
3.	Jung, Yi-Sook: 1 article (05/2017)
4.	Kim, Tae-Ho: 1 article (05/2017)
5.	Kim, Young-Ae: 1 article (05/2017)
6.	Lee, Dong Gil: 1 article (05/2017)
7.	Lee, Jeong Hyun: 1 article (03/2017)
8.	Lim, Chae Jo: 1 article (03/2017)
9.	Oh, Kwang-Seok: 1 article (03/2017)
10.	Park, Byung Kil: 1 article (03/2017)

Related Diseases

1.	Heart Failure 03/15/2017 - "In myocardial infarction-induced chronic heart failure model in rats, repeated echocardiography and hemodynamic measurements demonstrated remarkable improvement of the cardiac performance by KR-36996 treatment (25 and 50mg/kg/day, p.o.) for 12 weeks. " 03/15/2017 - "A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure."
2.	Cardiomegaly (Heart Hypertrophy) 03/15/2017 - "In transverse aortic constriction-induced cardiac hypertrophy model in mice, the daily oral administration of KR-36996 (30mg/kg) for 14 days significantly decreased left ventricular weight by 40% (P<0.05). " 03/15/2017 - "A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure."
3.	Hypertrophy 03/15/2017 - "In cell-based study, KR-36996 significantly inhibited urotensin II-induced stress fiber formation and cellular hypertrophy in H9c2UT cells. " 03/15/2017 - "Moreover, KR-36996 decreased interstitial fibrosis and cardiomyocyte hypertrophy in the infarct border zone. "
4.	Atherosclerosis 05/01/2017 - "These results suggest that KR-36996 is a better candidate than GSK-1440115 in preventing vascular proliferation in the pathogenesis of atherosclerosis and restenosis."
5.	Myocardial Infarction 03/15/2017 - "In myocardial infarction-induced chronic heart failure model in rats, repeated echocardiography and hemodynamic measurements demonstrated remarkable improvement of the cardiac performance by KR-36996 treatment (25 and 50mg/kg/day, p.o.) for 12 weeks. "

Related Drugs and Biologics

1.	urotensin II
2.	4'-(1-(((6,7-dichloro-3- oxo- 2,3- dihydro- 4H- 1,4- benzoxazin- 4- yl)acetyl)(methyl)amino)- 2- (4- morpholinyl)ethyl)- 4- biphenylcarboxylic acid

Related Therapies and Procedures

1.	Oral Administration